Blood levels do not predict behavioral or physiological effects of δ9-tetrahydrocannabinol in rhesus monkeys with different patterns of exposure

Drug and Alcohol Dependence

Volumn 139, Issue , 2014, Pages 1-8

  Ginsburg, Brett C ^a   Hruba, Lenka ^a,b   Zaki, Armia ^a   Javors, Martin A ^a   McMahon, Lance R ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

11 OH THC; Driving under the influence; DUI; Legal limit; Marijuana; Rhesus; THC COOH

Indexed keywords

DRONABINOL; DRUG METABOLITE;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RECTUM TEMPERATURE; RHESUS MONKEY; STIMULUS RESPONSE; ANIMAL; BLOOD; BODY TEMPERATURE; DRUG ADMINISTRATION; DRUG EFFECTS; HALF LIFE TIME; PSYCHOMOTOR PERFORMANCE;

CANNABIS; CANNABIS SATIVA; MACACA MULATTA;

ANIMALS; BODY TEMPERATURE; CONDITIONING, OPERANT; DRONABINOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; MACACA MULATTA; MALE; PSYCHOMOTOR PERFORMANCE;

EID: 84899991145     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.02.696     Document Type: Article

References (49)

1. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Methodol. 1995, 57:289-300.
2. Bergamaschi M.M., Karschner E.L., Goodwin R.S., Scheidweiler K.B., Hirvonen J., Queiroz R.H.C., Heustis M.A. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin. Chem. 2013, 59:519-526.
3. Bosker W.M., Kuypers K.P.C., Theunissen E.L., Surinx A., Blankespoor R.J., Skopp G., Jeffery W.K., Walls H.C., van Leeuwen C.J., Ramaekers J.G. Medicinal δ(9)-tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests. Addiction 2012, 107:1837-1844.
4. Cascini F., Aiello C., Di Tanna G. Increasing delta-9-tetrahydrocannabinol (δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr. Drug Abuse Rev. 2012, 5:32-40.
5. Dewey W.L., McMillan D.E., Harris L.S., Turk R.F. Distribution of radioactivity in brain of tolerant and nontolerant pigeons treated with 3H-9-tetrahydrocannabinol. Biochem. Pharmacol. 1973, 22:399-405.
6. Downey L.A., King R., Papafotiou K., Swann P., Ogden E., Boorman M., Stough C. The effects of cannabis and alcohol on simulated driving: influences of dose and experience. Accid. Anal. Prev. 2013, 50:879-886.
7. D'Souza D.C., Ranganathan M., Braley G., Gueorguieva R., Zimolo Z., Cooper T., Perry E., Krystal J. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 2008, 33:2505-2516.
8. Fan F., Compton D.R., Ward S., Melvin L., Martin B.R. Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J. Pharmacol. Exp. Ther. 1994, 271:1383-1390.
9. Ginsburg B.C., Martinez G., Friesenhahn G., Javors M., Lamb R.J. Acute tolerance to rate-decreasing effects of single doses of ethanol. Physiol. Behav. 2008, 94:374-383.
10. 9-tetrahydrocannabinol-like discriminative stimulus effects in monkeys. J. Pharmacol. Exp. Ther. 2012, 340:37-45.
11. Grotenhermen F., Leson G., Berghaus G., Drummer O.H., Krüger H.-P., Longo M., Moskowitz H., Perrine B., Ramaekers J.G., Smiley A., Tunbridge R. Developing limits for driving under cannabis. Addiction 2007, 102:1910-1917.
12. Hartman H.L. Legalized marijuana and the workplace: preparing for the trend. Employee Relat. Law J. 2013, 38:72-75.
13. Hartman R.L., Huestis M.A. Cannabis effects on driving skills. Clin. Chem. 2013, 59:478-492.
14. Hiltunen A.J., Järbe T.U. Acute and chronic ethanol tolerance: operant behaviour in naive and ethanol tolerant rats. Psychopharmacology (Berl.) 1992, 107:511-516.
15. Hollister L.E., Gillespie H.K., Ohlsson A., Lindgren J.E., Wahlen A., Agurell S. Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication?. J. Clin. Pharmacol. 1981, 21. 171S-177S.
16. 9-tetrahydrocannabinol treatment in rhesus monkeys. J. Pharmacol. Exp. Ther. 2012, 342:843-849.
17. Huestis M.A. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb. Exp. Pharmacol. 2005, 657-690.
18. Huestis M.A., Cone E.J. Relationship of Delta 9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J. Anal. Toxicol. 2004, 28:394-399.
19. Hunault C.C., Mensinga T.T., de Vries I., Kelholt-Dijkman H.H., Hoek J., Kruidenier M., Leenders M.E., Meulenbelt J. Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69mg THC. Psychopharmacology (Berl.) 2008, 20:171-181.
20. Hunt C.A., Jones R.T. Tolerance and disposition of tetrahydrocannabinol in man. J. Pharmacol. Exp. Ther. 1980, 215:35-44.
21. Järbe T.U. delta9-Tetrahydrocannabinol: tolerance after noncontingent exposure in rats. Arch. Int. Pharmacodyn. Ther. 1978, 231:49-56.
22. Karschner E.L., Schwope D.M., Schwilke E.W., Goodwin R.S., Kelly D.L., Gorelick D.A., Huestis M.A. Predictive model accuracy in estimating last δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug Alcohol Depend. 2012, 125:313-319.
23. Lamb R.J., Järbe T.U., Makriyannis A., Lin S., Goutopoulos A. Effects of Delta 9-tetrahydrocannabinol, (R)-methanandamide, SR141716,and d-amphetamine before and during daily Delta 9-tetrahydrocannabinol dosing. Eur. J. Pharmacol. 2000, 398:251-258.
24. Lile J.A., Kelly T.H., Pinsky D.J., Hays L.R. Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol. Psychopharmacology (Berl.) 2009, 203:241-250.
25. Lomax P. Acute tolerance to the hypothermic effect of marijuana in the rat. Res. Commun. Chem. Pathol. Pharmacol. 1971, 2:159-167.
26. Martin B.R., Dewey W.L., Harris L.S., Beckner J.S. 3H-delta9-tetrahydrocannabinol tissue and subcellular distribution in the central nervous system and tissue distribution in peripheral organs of tolerant and nontolerant dogs. J. Pharmacol. Exp. Ther. 1976, 196:128-144.
27. Matsuzaki M., Casella G.A., Ratner M. delta 9-Tetrahydrocannabinol: EEG changes, bradycardia and hypothermia in the rhesus monkey. Brain Res. Bull. 1987, 19:223-229.
28. McKinney D.L., Cassidy M.P., Collier L.M., Martin B.R., Wiley J.L., Selley D.E., Sim-Selley L.J. Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 2008, 324:664-673.
29. McMahon L.R., Amin M.R., France C.P. SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys. Behav. Pharmacol. 2005, 16:363-372.
30. McMahon L.R. Chronic (9-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids. Br. J. Pharmacol. 2011, 162:1060-1073.
31. McMillan D.E., Leander J.D., Dudley K.H. Effects of drugs on behavior in pigeons tolerant to delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 1980, 212:85-90.
32. Miczek K.A. Chronic delta9-tetrahydrocannabinol in rats: effect on social interactions, mouse killing, motor activity, consummatory behavior, and body temperature. Psychopharmacology (Berl.) 1979, 60:137-146.
33. Moskowitz H., Fiorentino D. A Review of the Literature on the Effects of Low Doses of Alcohol on Driving-Related Skills 2000, National Highway Traffic Safety Administration, Washington, DC.
34. Ramaekers J.G., Kauert G., Theunissen E.L., Toennes S.W., Moeller M.R. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J. Psychopharmacol. Oxford 2009, 23:266-277.
35. R Development Core Team, 2012. R: A Language and Environment for Statistical Computing R. Foundation for Statistical Computing, Vienna, Austria.
36. Sachse-Seeboth C., Pfeil J., Sehrt D., Meineke I., Tzvetkov M., Bruns E., Poser W., Vormfelde S.V., Brockmöller J. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin. Pharmacol. Ther. 2009, 85:273-276.
37. 9-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. J. Anal. Toxicol. 2012, 36:405-412.
38. Schulze G.E., McMillan D.E., Bailey J.R., Scallet A., Ali S.F., Slikker W., Paule M.G. Acute effects of delta-9-tetrahydrocannabinol in rhesus monkeys as measured by performance in a battery of complex operant tests. J. Pharmacol. Exp. Ther. 1988, 245:178-186.
39. Seamon M.J. The legal status of medical marijuana. Ann. Pharmacother. 2006, 40:2211-2215.
40. Singh H., Schulze D.R., McMahon L.R. Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia. Psychopharmacology (Berl.) 2011, 215:665-675.
41. Slikker W., Paule M.G., Ali S.F., Scallet A.C., Bailey J.R. Chronic marijuana smoke exposure in the rhesus monkey. I. Plasma cannabinoid and blood carboxyhemoglobin concentrations and clinical chemistry parameters. Fundam. Appl. Toxicol. 1991, 17:321-334.
42. Stott C.G., White L., Wright S., Wilbraham D., Guy G.W. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. Eur. J. Clin. Pharmacol. 2013, 69:825-834.
43. 9 Tetrahydrocannabinol attenuates MDMA-induced hyperthermia in rhesus monkeys. Neuroscience 2012, 201:125-133.
44. 9 Tetrahydrocannabinol impairs visuo-spatial associative learning and spatial working memory in rhesus macaques. J. Psychopharmacol. 2012, 26:1299-1306.
45. Toennes S.W., Schneider K., Kauert G.F., Wunder C., Moeller M.R., Theunissen E.L., Ramaekers J.G. Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. Anal. Bioanal. Chem. 2011, 400:145-152.
46. Uran B., Tulunay F.C., Ayhan I.H., Ulkü E., Kaymakçalan S. Correlation between the dose and development of acute tolerance to the hypothermic effect of THC. Pharmacology 1980, 21:391-395.
47. Walker, S., Fields, R., King, S., 2013. A bill for an act concerning penalties for persons who drive while under the influence of alcohol or drugs and in connection therewith making an appropriation. House Bill 114. Colorado State Assembly.
48. Wiley J.L. Cannabis: discrimination of "internal bliss"?. Pharmacol. Biochem. Behav. 1999, 64:257-260.
49. Winsauer P.J., Lambert P., Moerschbaecher J.M. Cannabinoid ligands and their effects on learning and performance in rhesus monkeys. Behav. Pharmacol. 1999, 10:497-511.